Is Mercury Labs overvalued or undervalued?

Aug 13 2025 08:01 AM IST
share
Share Via
As of August 12, 2025, Mercury Labs is fairly valued with a PE ratio of 31.94 and an EV to EBITDA of 14.77, while underperforming the Sensex with a return of -13.39%, compared to its peers Sun Pharma and Cipla.
As of 12 August 2025, Mercury Labs has moved from an expensive valuation grade to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 31.94, an EV to EBITDA of 14.77, and a Price to Book Value of 1.87.

In comparison to its peers, Sun Pharma has a PE ratio of 33.93 and an EV to EBITDA of 22.96, indicating it is considered expensive, while Cipla is rated attractive with a PE of 22.77 and an EV to EBITDA of 16.01. Notably, Mercury Labs has a PEG ratio of 0.00, which suggests potential growth opportunities. Over the past year, the stock has underperformed the Sensex, with a return of -13.39% compared to the Sensex's 0.74%, reinforcing the notion that the stock is currently fairly valued.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News